Publications 2024

Pinto R, Vedeld HM, Lind GE, Jeanmougin M (2024)
Unraveling epigenetic heterogeneity across gastrointestinal adenocarcinomas through a standardized analytical framework
Mol Oncol (in press)
DOI 10.1002/1878-0261.13772, PubMed 39696831

Vedeld HM, Pharo H, Sørbø AK, Brandt-Winge S, Five MB, Jeanmougin M, Guldberg P, Wahlqvist R, Lind GE (2024)
Distinct longitudinal patterns of urine tumor DNA in patients undergoing surveillance for bladder cancer
Mol Oncol, 18 (11), 2684-2695
DOI 10.1002/1878-0261.13639, PubMed 38720532

Publications 2023

Jeanmougin M, Brodal HP, Dietrichson Pharo H, Vedeld HM, Lind GE (2023)
PoDCall: positive droplet calling and normalization of droplet digital PCR DNA methylation data
Bioinformatics, 39 (1)
DOI 10.1093/bioinformatics/btac766, PubMed 36448696

Kresse SH, Brandt-Winge S, Pharo H, Flatin BTB, Jeanmougin M, Vedeld HM, Lind GE (2023)
Evaluation of commercial kits for isolation and bisulfite conversion of circulating cell-free tumor DNA from blood
Clin Epigenetics, 15 (1), 151
DOI 10.1186/s13148-023-01563-0, PubMed 37710283

Publications 2022

Pharo HD, Jeanmougin M, Ager-Wick E, Vedeld HM, Sørbø AK, Dahl C, Larsen LK, Honne H, Brandt-Winge S, Five MB, Monteiro-Reis S, Henrique R, Jeronimo C, Steven K, Wahlqvist R, Guldberg P, Lind GE (2022)
BladMetrix: a novel urine DNA methylation test with high accuracy for detection of bladder cancer in hematuria patients
Clin Epigenetics, 14 (1), 115
DOI 10.1186/s13148-022-01335-2, PubMed 36115961

Publications 2021

Vedeld HM, Grimsrud MM, Andresen K, Pharo HD, von Seth E, Karlsen TH, Honne H, Paulsen V, Färkkilä MA, Bergquist A, Jeanmougin M, Aabakken L, Boberg KM, Folseraas T, Lind GE (2021)
Early and accurate detection of cholangiocarcinoma in patients with primary sclerosing cholangitis by methylation markers in bile
Hepatology, 75 (1), 59-73
DOI 10.1002/hep.32125, PubMed 34435693

Publications 2020

Flatin BTB, Vedeld HM, Pinto R, Langerud J, Lind GE, Lothe RA, Sveen A, Jeanmougin M (2020)
Multiregional assessment of CIMP in primary colorectal cancers: Phenotype concordance but marker variability
Int J Cancer, 148 (7), 1652-1657
DOI 10.1002/ijc.33425, PubMed 33284993

Vedeld HM, Folseraas T, Lind GE (2020)
Detecting cholangiocarcinoma in patients with primary sclerosing cholangitis - The promise of DNA methylation and molecular biomarkers
JHEP Rep, 2 (5), 100143
DOI 10.1016/j.jhepr.2020.100143, PubMed 32939446

Publications 2019

Marcuello M, Vymetalkova V, Neves RPL, Duran-Sanchon S, Vedeld HM, Tham E, van Dalum G, Flügen G, Garcia-Barberan V, Fijneman RJ, Castells A, Vodicka P, Lind GE, Stoecklein NH, Heitzer E, Gironella M (2019)
Circulating biomarkers for early detection and clinical management of colorectal cancer
Mol Aspects Med, 69, 107-122
DOI 10.1016/j.mam.2019.06.002, PubMed 31189073

Publications 2018

Pinto D, Pinto C, Guerra J, Pinheiro M, Santos R, Vedeld HM, Yohannes Z, Peixoto A, Santos C, Pinto P, Lopes P, Lothe R, Lind GE, Henrique R, Teixeira MR (2018)
Contribution of MLH1 constitutional methylation for Lynch syndrome diagnosis in patients with tumor MLH1 downregulation
Cancer Med, 7 (2), 433-444
DOI 10.1002/cam4.1285, PubMed 29341452

Vedeld HM, Nesbakken A, Lothe RA, Lind GE (2018)
Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
Clin Epigenetics, 10, 70
DOI 10.1186/s13148-018-0503-2, PubMed 29854011

Publications 2017

Vedeld HM, Goel A, Lind GE (2017)
Epigenetic biomarkers in gastrointestinal cancers: The current state and clinical perspectives
Semin Cancer Biol, 51, 36-49
DOI 10.1016/j.semcancer.2017.12.004, PubMed 29253542

Vedeld HM, Merok M, Jeanmougin M, Danielsen SA, Honne H, Presthus GK, Svindland A, Sjo OH, Hektoen M, Eknaes M, Nesbakken A, Lothe RA, Lind GE (2017)
CpG island methylator phenotype identifies high risk patients among microsatellite stable BRAF mutated colorectal cancers
Int J Cancer, 141 (5), 967-976
DOI 10.1002/ijc.30796, PubMed 28542846

Publications 2016

Pharo HD, Honne H, Vedeld HM, Dahl C, Andresen K, Liestøl K, Jeanmougin M, Guldberg P, Lind GE (2016)
Experimental factors affecting the robustness of DNA methylation analysis
Sci Rep, 6, 33936
DOI 10.1038/srep33936, PubMed 27671843

Publications 2015

Andresen K, Boberg KM, Vedeld HM, Honne H, Jebsen P, Hektoen M, Wadsworth CA, Clausen OP, Lundin KE, Paulsen V, Foss A, Mathisen Ø, Aabakken L, Schrumpf E, Lothe RA, Lind GE (2015)
Four DNA methylation biomarkers in biliary brush samples accurately identify the presence of cholangiocarcinoma
Hepatology, 61 (5), 1651-9
DOI 10.1002/hep.27707, PubMed 25644509

Publications 2014

Vedeld HM, Andresen K, Eilertsen IA, Nesbakken A, Seruca R, Gladhaug IP, Thiis-Evensen E, Rognum TO, Boberg KM, Lind GE (2014)
The novel colorectal cancer biomarkers CDO1, ZSCAN18 and ZNF331 are frequently methylated across gastrointestinal cancers
Int J Cancer, 136 (4), 844-53
DOI 10.1002/ijc.29039, PubMed 24948044

Vedeld HM, Skotheim RI, Lothe RA, Lind GE (2014)
The recently suggested intestinal cancer stem cell marker DCLK1 is an epigenetic biomarker for colorectal cancer
Epigenetics, 9 (3), 346-50
DOI 10.4161/epi.27582, PubMed 24384857

Publications 2012

Andresen K, Boberg KM, Vedeld HM, Honne H, Hektoen M, Wadsworth CA, Clausen OP, Karlsen TH, Foss A, Mathisen O, Schrumpf E, Lothe RA, Lind GE (2012)
Novel target genes and a valid biomarker panel identified for cholangiocarcinoma
Epigenetics, 7 (11), 1249-57
DOI 10.4161/epi.22191, PubMed 22983262